EXPERTISE
CMC & Regulatory Integration
Designing development pathways that are not only scientifically sound, but also manufacturable, compliant, and aligned with global regulatory expectations.
The Challenge
- Many development programmes face delays due to late-stage regulatory and CMC misalignment
- Formulations optimised for performance may not be scalable or manufacturable
- Regulatory expectations are often addressed too late in development
- This leads to rework, delays, increased costs, and approval risk
The Challenge
- Early-stage molecules often lack the physicochemical stability required for downstream development
- Poor solid-state characteristics can compromise manufacturability and scalability
- Limited early characterisation leads to late-stage failures and reformulation cycles
CMC Strategy from Day One
Aligning formulation development with manufacturing feasibility and regulatory expectations early in the process
Regulatory Pathway Planning
Defining development strategies aligned with global regulatory frameworks and submission requirements
Formulation–Manufacturing Alignment
Ensuring formulations are designed for scalability, robustness, and reproducibility
Documentation & Compliance Readiness
Structuring development data and documentation to support regulatory submissions and audits
Early alignment of formulation and CMC strategy prevented scale-up failure and enabled seamless transition into clinical manufacturing.
Where We Prevent Development Risk
Non-Scalable Formulations
When promising formulations fail during scale-up or manufacturing
Regulatory Misalignment
When development does not meet expectations for approval pathways
Late-Stage Rework
When critical issues are discovered too late, requiring costly redesign
Documentation Gaps
When data is insufficient or poorly structured for regulatory submission
Early alignment of formulation and CMC strategy prevented scale-up failure and enabled seamless transition into clinical manufacturing.
Outcomes
- Development programmes aligned with global regulatory expectations
- Scalable, robust formulations ready for manufacturing
- Reduced risk of late-stage failure and rework
- Efficient progression through clinical and regulatory milestones
- Stronger readiness for submission and approval
Where We Prevent Development Risk
Integrated throughout development to ensure that formulation, manufacturing, and regulatory strategy evolve together — reducing risk and enabling smooth progression from early development to approval.
Preparing for scale-up or regulatory progression?
Partner with Dhee Lifesciences to ensure your development programme is aligned, compliant, and ready for execution.
